Navigation Links
First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease
Date:5/4/2009

Fort Lauderdale, FL (May 4, 2009): Uveitis, or inflammation within the eye, is a group of diseases responsible for years of visual loss roughly comparable to that caused by diabetes. Now, results from a pioneering international Phase 3 program in uveitis, the LUMINATE trials sponsored by Lux Biosciences, demonstrate the ability of LX211 (LUVENIQ, voclosporin oral capsule) to significantly improve this chronic eye inflammation. Additionally, in patients who are discontinuing potentially toxic medications for uveitis, such as the corticosteroid prednisone, LX211 actively reduces the rate of inflammatory exacerbations by 50% at six months, compared to placebo. The study results also show a safety profile for LX211 at the 0.4 mg/kg bid dose that suggests the experimental drug would be suitable for chronic use as the first oral treatment for this sight-threatening inflammatory eye disease, while also providing a means to greatly reduce the serious health risks associated with long-term corticosteroid use. LX211 is a novel and proprietary next-generation calcineurin inhibitor that Lux Biosciences is developing for ophthalmic uses.

Dr. James T. Rosenbaum, M.D., Professor of Ophthalmology, Medicine and Cell Biology and Vice-Chair of the Department of Ophthalmology of the Casey Eye Institute Oregon Health Sciences University (OHSU), represented the LUMINATE Investigator Network in presenting the Phase 3 LUMINATE program results for the first time at the 2009 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The LUMINATE program, consisting of three randomized, double-masked, dose-ranging and placebo-controlled trials that enrolled a total of 558 patients at 56 sites in 7 countries (United States, Canada, United Kingdom, France, Germany, Austria and India), is the largest clinical program ever conducted in uveitis.

"Uveitis, a term used to classify a group of autoimmune diseases characterized by chronic inflammation of
'/>"/>

Contact: Joan Kureczka
JKureczka@comcast.net
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
2. Meso Scale Diagnostics Point of Care Influenza Test Led to the First Identification of A(H1N1) Swine Flu Infection
3. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
4. First H1N1 Swine Flu Vaccine, Replikins-Based, Is Ready Now for Testing Worldwide
5. Elsevier Health Sciences Appoints Dr. David Goldmann Editor-in-Chief of its First Consult Point of Care Resource
6. The first DFG research centers to be funded for another 4 years
7. TorreyPines Therapeutics Reports First Quarter 2009 Financial Results
8. Biotech Drops on Weaker First Quarter Drug Sales, But Broader Markets Remain on a Roll
9. First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals GGTI-2418
10. United Therapeutics Reports First Quarter 2009 Financial Results
11. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2014)... University of Pennsylvania researchers has now applied a ... other nanoscopic structures. By passing nanoscale spheres and ... the team was able to measure the electrical ... suggest new ways of using this technique, known ... smallest scale. , The research was led ...
(Date:9/26/2014)... Research and Markets  has announced the ... Markets: Market Developments, Growth Areas and Opportunities" report ... comprehensive global end-user study and market analysis relating to ... in the laboratory. Market findings from this ... by research scientists and clinicians who routinely use nucleic ...
(Date:9/26/2014)... Molecular Biology deals with the ... regulation of cellular activity and its behaviour. It emphasise ... with its environment within the genome. Knowledge on molecular ... therapeutic methodologies for the diagnosis, prognosis and the treatment ... Dr. Srinubabu Gedela, MD of OMICS Publishing Group ...
(Date:9/26/2014)... (PRWEB) September 26, 2014 Talon ... and Assemblies for the Semiconductor, Medical Device, ... it has won the Minnesota Business magazine’s Employee ... companies for excellence in helping Minnesota-based employees improve ... in our people, our processes and our capabilities ...
Breaking Biology Technology:Penn team studies nanocrystals by passing them through tiny pores 2Penn team studies nanocrystals by passing them through tiny pores 3Penn team studies nanocrystals by passing them through tiny pores 4DNA and RNA Sample Preparation Markets: Market Developments, Growth Areas and Opportunities 2DNA and RNA Sample Preparation Markets: Market Developments, Growth Areas and Opportunities 3Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 3Talon Innovations Wins Minnesota Business Magazine Award 2Talon Innovations Wins Minnesota Business Magazine Award 3
... Educational program offers unique resources to empower transplant patients ... ... Oct. 17 Astellas Pharma US,Inc. (Pink Sheets: ALPMF), a ... Society (ITNS), a leading transplant,professional organization, announced a collaborative partnership ...
... to Dominate the Type 2 Diabetes Market, According to a ... New Report from Decision Resources, ... have released a new report finding that Merck,will obtain blockbuster antidiabetic ... uptake of their DPP-IV inhibitor, Januvia.,Januvia will see rapid uptake as ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 2Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011 3Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2
(Date:9/29/2014)... annual Advocacy Awards will ... advancing medical progress to improve the health and ... take place on Wednesday, March 11, 2015, at ... , The 2015 Advocacy Award winners are ABC,s ... founder of the Milken Institute and FasterCures; Dr. ...
(Date:9/29/2014)... beginning of the age of dinosaurs, gigantic reptilesdistant relatives ... and others in water and it was thought they ... University of Tennessee, Knoxville, researcher in the thigh of ... , Stephanie Drumheller, an earth and planetary sciences ... Sterling Nesbitt examined 220-million-year-old bite marks in the thigh ...
(Date:9/29/2014)... Institute (DOE JGI), a DOE Office of Science ... have been selected for the 2015 Community Science ... waters, and from plant root micro-ecosystems, to the ... the CSP 2015 projects portfolio highlights diverse environments ... , "These projects catalyze JGI,s strategic shift in ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 4Tooth serves as evidence of 220 million-year-old attack 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... neighbors, and now researchers reporting in the June 22 issue ... they have a motive. It appears that chimps, and especially ... gain territory. "The take-home is clear and simple," ... each other. They kill their neighbors. Up until now, we ...
... which aims to develop a new, higher-yielding rice plant which could ... by an academic at the University of Sheffield. Currently, more ... a day and nearly one billion live in hunger. Over the ... about 50 per cent and water scarcity will grow. About half ...
... international public-private consortium to build the most detailed map ... of three pilot projects and the deposition of the ... use by the research community. In addition, work has ... database containing information from the genomes of 2,500 people ...
Cached Biology News:Why chimpanzees attack and kill each other 2Rice yields researched to tackle food security issues 2Rice yields researched to tackle food security issues 3Freely available data supporting next generation of human genetic research 2Freely available data supporting next generation of human genetic research 3Freely available data supporting next generation of human genetic research 4Freely available data supporting next generation of human genetic research 5Freely available data supporting next generation of human genetic research 6